Prof. Da Pang 庞达
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of benign and malignant breast tumors, including breast-conserving surgery, sentinel lymph node biopsy, mastectomy, and modified radical mastectomy. Focuses on early diagnosis, minimally invasive surgery for benign tumors, neoadjuvant therapy, and postoperative comprehensive care.
Dr. Pang is Chief Physician and Professor at Harbin Medical University Cancer Hospital, serving as Vice President and Director of Abdominal and Breast Surgery. Dr. Pang leads the provincial key discipline and heads the Heilongjiang Provincial Institute of Oncology. Research and clinical interests include breast cancer prevention, diagnosis, and novel surgical techniques such as breast-conserving surgery and sentinel lymph node biopsy.
Professional roles
- Chair, Breast Cancer Committee, Heilongjiang Anti-Cancer Association
- Standing Committee Member, Breast Cancer Committee, China Anti-Cancer Association
- Member, Breast Cancer Group, Chinese Medical Association
- Editor-in-Chief, Practical Oncology
Name order: in Chinese the family name comes first (Pang Da). Papers usually list the name as Da Pang or Pang D.
Selected publications
93 papers on PubMed matched by name and affiliation; 56 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Prediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning models. PubMed 42465567
- Oncogene, 2026 (senior author): CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer. PubMed 41986650
- Adv Sci (Weinh), 2026 (senior author): Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer. PubMed 41454718
- J Exp Clin Cancer Res, 2025 (senior author): H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer. PubMed 40849487
- iScience, 2025 (senior author): Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. PubMed 40606759
- Cancer Med, 2025 (senior author): An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing. PubMed 40539820
- Drug Resist Updat, 2025 (senior author): The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity. PubMed 40048957
- Int Immunopharmacol, 2024 (senior author): Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer. PubMed 39241517
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion